Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL011
MIFTS: 60

Oral Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Cancer

About this section

MalaCards integrated aliases for Oral Cancer:

Name: Oral Cancer 52 36 54 42 3
Lip and Oral Cavity Carcinoma 71
Malignant Neoplasm of Mouth 71

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


External Ids:

KEGG 36 H00016
UMLS 71 C0153381 C0220641
Sources

Summaries for Oral Cancer

About this section
KEGG : 36 Oral cancer refers to a subgroup of head and neck malignancies that develop at the lips, tongue, salivary glands, gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations, according to the International Classification of Diseases. Nevertheless, the term is synonymous to squamous cell carcinoma (SCC) of oral mucosal origin that accounts for more than 90% of all malignant presentations at the aforementioned anatomical sites. Worldwide, oral SCC (OSCC) is the sixth most common cancer; more than 300,000 new cases are diagnosed each year. The development of OSCC is a multistep process requiring the accumulation of multiple genetic alterations, influenced by a patient's genetic predisposition as well as by environmental influences, including tobacco, alcohol, chronic inflammation, and viral infection. The genetic changes include activation of the epidermal growth factor receptor (EGFR), alterations of tumor suppressors p53 and p16, and cyclin D1 overexpression.

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to oral submucous fibrosis and oral leukoplakia, and has symptoms including snoring and halitosis. An important gene associated with Oral Cancer is MIR31 (MicroRNA 31), and among its related pathways/superpathways are Endometrial cancer and Relaxin signaling pathway. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and testes, and related phenotypes are Reduced mammosphere formation and cardiovascular system

NIH Rare Diseases : 52 Oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). Most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells ) that cover the surfaces of the mouth, tongue, and lips. About 42,000 individuals in the United Stated are diagnosed with oral cancer each year. Most cases occur in people over age 40. Men are twice as likely to be affected as women. The use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. Other risk factors include HPV, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. Treatment for oral cancer may include surgery, radiation therapy , chemotherapy , or targeted therapy .

MedlinePlus : 42 Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

CDC : 3 In 2012, there were nearly 40,000 new cases of cancer of the oral cavity and pharynx diagnosed in the United States and nearly 9,000 deaths. The 5-year survival rate for these cancers is about 59 percent. Mortality from oral cancer is nearly twice as high in some minorities (especially black males) as it is in whites. Preventing high risk behaviors, that include cigarette, cigar or pipe smoking, use of smokeless tobacco, and excessive use of alcohol are critical in preventing oral cancers. Early detection is key to increasing the survival rate for these cancers. Oral Human Papilloma Virus (HPV), the most common sexually transmitted disease, can cause cancers in the back of the throat, called "oropharyngeal cancers." More research is needed to determine whether HPV itself causes oropharyngeal cancers, or if other factors (such as smoking or chewing tobacco) interact with HPV to cause these cancers.

Wikipedia : 74 Oral cancer, also known as mouth cancer, is cancer of the lining of the lips, mouth, or upper throat. In... more...

Sources

Related Diseases for Oral Cancer

About this section

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
# Related Disease Score Top Affiliating Genes
1 oral submucous fibrosis 32.4 TP53 MMP9 MMP2 GSTM1 CYP1A1 CDH1
2 oral leukoplakia 31.5 TP53 GSTM1 CDKN2A
3 leukoplakia 31.3 KRT13 GSTT1 GSTM1 CYP1A1
4 squamous cell papilloma 31.3 TP53 CDKN2A
5 oropharynx cancer 31.0 TP53 EGFR CDKN2A CDH1 CCND1
6 oral squamous cell carcinoma 30.7 TP53 MMP9 MMP2 MIR31 MIR21 EGFR
7 oral cavity cancer 30.7 MIR31 MIR21 GSTM1 EGFR CYP1A1
8 in situ carcinoma 30.6 TP53 EGFR CDKN2A CDH1 CCND1
9 tongue carcinoma 30.5 TP53 MMP9 MMP2 MIR31 MIR21 CDH1
10 papilloma 30.5 TP53 KRT13 EGFR CDKN2A CDH1 CCND1
11 salivary gland carcinoma 30.3 TP53 GSTM1 EGFR CDKN2A
12 keratosis 30.3 TP53 MMP9 MMP2 EGFR CDKN2A
13 mutagen sensitivity 30.2 TP53 GSTT1 GSTM1 CCND1
14 verrucous carcinoma 30.1 TP53 MMP9 MIR31 EGFR CDKN2A CCND1
15 keratocystic odontogenic tumor 30.0 TP53 MMP9 CCND1
16 tonsil cancer 30.0 TP53 EGFR CDKN2A CDH1
17 osteogenic sarcoma 30.0 TP53 MMP9 MMP2 CDKN2A
18 skin melanoma 30.0 TP53 MMP9 MMP2 CDKN2A
19 li-fraumeni syndrome 30.0 TP53 EGFR CDKN2A CDH1
20 anus cancer 30.0 TP53 EGFR CDKN2A
21 tongue squamous cell carcinoma 29.9 TP53 MMP9 MMP2 MIR21 EGFR CDKN2A
22 gastrointestinal carcinoma 29.9 TP53 MMP2 KRT19
23 adenoma 29.9 TP53 CDKN2A CDH1 CCND1
24 esophagitis 29.8 TP53 EGFR CDKN2A
25 hypopharynx cancer 29.8 TP53 EGFR CDKN2A CDH1
26 adenocarcinoma 29.8 TP53 MMP9 MMP2 EGFR CDKN2A CDH1
27 squamous cell carcinoma 29.8 TP53 MMP9 MMP2 KRT19 KRT13 EGFR
28 retinitis pigmentosa 11 29.8 TP53 EGFR CDKN2A
29 pulmonary disease, chronic obstructive 29.8 MMP9 MIR21 GSTM1 CYP1A1
30 ameloblastoma 29.8 TP53 MMP9 MMP2 KRT19
31 wilms tumor 1 29.7 TP53 EGFR CDH1 CCND1
32 small cell carcinoma 29.7 TP53 KRT19 EGFR CDKN2A
33 breast adenocarcinoma 29.6 TP53 MMP9 MMP2 EGFR CYP1A1
34 mucoepidermoid carcinoma 29.5 TP53 KRT19 KRT13 EGFR CDKN2A CDH1
35 suppressor of tumorigenicity 3 29.5 TP53 CDKN2A
36 kidney cancer 29.5 TP53 MIR21 GSTM1 EGFR CDKN2A
37 small cell cancer of the lung 29.4 TP53 MIR21 KRT19 EGFR CDKN2A
38 cervical squamous cell carcinoma 29.4 TP53 MMP2 EGFR CDKN2A CDH1 CCND1
39 adenoid cystic carcinoma 29.4 TP53 MMP9 MMP2 KRT19 EGFR CDKN2A
40 leukemia, acute lymphoblastic 29.3 TP53 MIR21 GSTT1 GSTM1 CYP1A1 CDKN2A
41 colon adenocarcinoma 29.3 TP53 MMP2 MIR21 EGFR CDH1 CCND1
42 melanoma 29.3 TP53 MMP2 MIR31 EGFR CDKN2A CDH1
43 skin carcinoma 29.1 TP53 MIR31 MIR21 GSTM1 EGFR CDKN2A
44 pharynx cancer 29.1 TP53 MIR31 MIR21 GSTM3 GSTM1 EGFR
45 glioblastoma multiforme 29.1 TP53 MMP9 MMP2 MIR21 EGFR CDKN2A
46 lymphoma, non-hodgkin, familial 29.0 TP53 MIR31 MIR21 GSTM1 CDKN2A CCND1
47 basal cell carcinoma 28.8 TP53 MMP9 KRT19 GSTT1 GSTM3 GSTM1
48 laryngeal squamous cell carcinoma 28.7 TP53 MMP2 MIR21 KRT19 GSTM3 GSTM1
49 leukemia, acute myeloid 28.6 TP53 MMP9 MIR31 MIR21 EGFR CDKN2A
50 larynx cancer 28.6 TP53 MMP2 MIR31 MIR21 GSTM3 GSTM1

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer
Sources

Symptoms & Phenotypes for Oral Cancer

About this section

UMLS symptoms related to Oral Cancer:


snoring, halitosis

GenomeRNAi Phenotypes related to Oral Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CDH1 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Oral Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ANO1 CCND1 CDH1 CDKN2A EGFR KRT19
2 growth/size/body region MP:0005378 9.93 ANO1 CCND1 CDH1 CDK2AP1 CDKN2A CYP1A1
3 digestive/alimentary MP:0005381 9.91 ANO1 CCND1 CDH1 CDKN2A EGFR KRT19
4 craniofacial MP:0005382 9.87 CCND1 CDK2AP1 EGFR KRT19 MMP2 RARB
5 neoplasm MP:0002006 9.56 CCND1 CDH1 CDKN2A EGFR KRT19 MMP2
6 respiratory system MP:0005388 9.28 ANO1 CCND1 CDKN2A EGFR KRT19 MMP2
Sources

Drugs & Therapeutics for Oral Cancer

About this section

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Dobutamine Approved Phase 4 34368-04-2 36811
7
Metformin Approved Phase 4 657-24-9 14219 4091
8 Adrenergic alpha-Agonists Phase 4
9 Adrenergic Agents Phase 4
10 Adrenergic Agonists Phase 4
11 Vasoconstrictor Agents Phase 4
12 Respiratory System Agents Phase 4
13 Epinephryl borate Phase 4
14 Dopamine Agents Phase 4
15 Adrenergic beta-Agonists Phase 4
16 Dopamine agonists Phase 4
17 Cardiotonic Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Vasodilator Agents Phase 4
20 Sympathomimetics Phase 4
21 Bronchodilator Agents Phase 4
22 Mydriatics Phase 4
23 Hypoglycemic Agents Phase 4
24
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
25
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 113775-47-6 5311068 68602
26
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
27
Fluorouracil Approved Phase 3 51-21-8 3385
28
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
29
Zinc Approved, Investigational Phase 3 7440-66-6 32051
30
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
31
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
32
Nicotine Approved Phase 2, Phase 3 54-11-5 942 89594
33
tannic acid Approved Phase 2, Phase 3 1401-55-4
34
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
35
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
36
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
39
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
40
Lobeline Investigational Phase 2, Phase 3 90-69-7
41 calcium heparin Phase 3
42 Coagulants Phase 3
43 Hypnotics and Sedatives Phase 2, Phase 3
44 Anesthetics, Intravenous Phase 2, Phase 3
45 Anesthetics, General Phase 2, Phase 3
46 Micronutrients Phase 3
47 Vitamins Phase 2, Phase 3
48 Trace Elements Phase 3
49 Nutrients Phase 3
50 Nicotinic Agonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 203)
# Name Status NCT ID Phase Drugs
1 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
2 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
3 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial Recruiting NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
4 Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. Unknown status NCT00655421 Phase 3
5 Interventional Study of Dexmedetomidine for Sedating Anticipated Difficult Airway Patients Undergoing Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
6 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
7 Phase III Trial of Surgery Followed by Conventional RT(5fr/Week)Vs.Concurrent Chemo-Radiotherapy Vs.Accelerated RT(6fr/Week)in High Risk, Loco-Regionally Advanced, Stage III&IVA, Resectable, Squamous Cell Carcinomas of Oralcavity Unknown status NCT00193843 Phase 3
8 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
9 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
10 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
11 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
12 Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial Completed NCT03824925 Phase 3 Placebo oral Zinc capsule;Zinc Sulfate 220 MG
13 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
14 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use Completed NCT00939029 Phase 2, Phase 3 nicotine replacement therapy (nicotine patches);placebo NRT
15 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
16 Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers. Completed NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
17 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
18 Multicentre，A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
19 Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) Terminated NCT00537199 Phase 3 OraTest
20 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
21 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
22 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
23 Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study Unknown status NCT00760682 Phase 2
24 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
25 Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity Completed NCT00953849 Phase 1, Phase 2 Celecoxib;Calcitriol;Celecoxib plus Calcitriol
26 Efficacy of Implant-Supported Maxillofacial Prostheses Completed NCT00006341 Phase 2
27 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Completed NCT03638622 Phase 1, Phase 2
28 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
29 Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
30 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
31 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
32 Efficacy of Varenicline for Smokeless Tobacco Use in India Completed NCT01098305 Phase 2 Varenicline
33 A Study of the Effects of PEITC on Oral Cells With Mutant p53 Completed NCT01790204 Phase 1, Phase 2
34 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
35 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
36 Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use of Lauryl-Diethylene-Glycol-Ether Sodium Sulfate Associated With Calcium Hydroxide (hCt20). Completed NCT00741754 Phase 2
37 A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03254927 Phase 2 CDX-3379 and cetuximab
38 A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Recruiting NCT03529422 Phase 2 Durvalumab
39 M4OC-Prevent: Metformin for Oral Cancer Prevention Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
40 Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Active, not recruiting NCT02882282 Phase 2
41 A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Active, not recruiting NCT03515538 Phase 2 RRx-001;Cisplatin for injection
42 A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization Not yet recruiting NCT04065737 Phase 2 Sintilimab
43 Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging Not yet recruiting NCT04191460 Phase 2 cRGD-ZW800-1.
44 Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy Not yet recruiting NCT04251949 Phase 2
45 A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Not yet recruiting NCT03745846 Phase 2
46 Free Soft Tissue Graft in Treatment of Oral Lichen Planus Unknown status NCT00737854 Phase 1
47 The Safety and Efficacy of the Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis Completed NCT00584597 Phase 1 Saline;Traumeel S;Traumeel S;Traumeel S
48 A Multicenter Phase I Safety and Tolerability Study of the Oncolux System for Intratumoral Delivery of Non-Coherent Light for the Photoactivation of LS 11 in Patients With Refractory Solid Tumors Completed NCT00028405 Phase 1 LS 11(Taporfin Sodium)
49 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
50 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin

Search NIH Clinical Center for Oral Cancer

Sources

Genetic Tests for Oral Cancer

About this section
Sources

Anatomical Context for Oral Cancer

About this section

MalaCards organs/tissues related to Oral Cancer:

40
Tongue, Lymph Node, Testes, Bone, Endothelial, Lung, Salivary Gland
Sources

Publications for Oral Cancer

About this section

Articles related to Oral Cancer:

(show top 50) (show all 11570)
# Title Authors PMID Year
1
Effects of lung protective ventilation on postoperative pulmonary outcomes for prolonged oral cancer combined with free flap surgery. 42 61
32000439 2020
2
Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. 61 46
20233326 2010
3
Diminished CD68+ Cancer-Associated Fibroblast Subset Induces Regulatory T-Cell (Treg) Infiltration and Predicts Poor Prognosis of Oral Squamous Cell Carcinoma Patients. 42
32035062 2020
4
Stathmin guides personalized therapy in oral squamous cell carcinoma. 42
31994271 2020
5
Diagnostic clinical aids in oral cancer. 61 54
20371204 2010
6
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 54 61
20040021 2010
7
Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. 61 54
20302655 2010
8
[Expression of survivin, caspase-3 in oral precancerous lesions and oral squamous-cell carcinoma]. 54 61
20368001 2010
9
Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. 61 54
19879255 2010
10
Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. 61 54
19653276 2010
11
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression. 54 61
19910795 2010
12
Modulation of EGFR by oral squamous cell carcinoma cell lines. 54 61
20066875 2009
13
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 46
19776030 2009
14
The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. 61 54
19717330 2009
15
S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. 54 61
19157822 2009
16
Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. 54 61
19431196 2009
17
Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. 61 54
19009234 2009
18
Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. 61 54
20160357 2009
19
Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. 61 54
19846940 2009
20
Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. 54 61
19373784 2009
21
Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. 61 54
20082880 2009
22
Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. 61 54
19204927 2009
23
Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. 61 54
19449077 2009
24
Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. 61 54
19340865 2009
25
CCL5/CCR5 axis promotes the motility of human oral cancer cells. 61 54
19334035 2009
26
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. 61 54
19391133 2009
27
Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. 61 54
19549906 2009
28
Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. 54 61
19525975 2009
29
Expression of Fas/FasL in patients with oral lichen planus. 61 54
19810143 2009
30
MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. 61 54
18804411 2009
31
Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. 61 54
18804405 2009
32
Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. 54 61
19489686 2009
33
Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. 54 61
19288014 2009
34
Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. 61 54
19414363 2009
35
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. 61 54
19197984 2009
36
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. 54 61
19239949 2009
37
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. 61 54
19276369 2009
38
E-Cadherin truncation and sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. 54 61
19152244 2009
39
Expression of p16 in oral cancer and premalignant lesions. 61 54
19192055 2009
40
Prevalence of CYP1A1 and GST polymorphisms in the population of northeastern India and susceptibility of oral cancer. 61 54
19718946 2009
41
CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. 54 61
19160101 2009
42
Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. 61 54
19729828 2009
43
GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case-control study in Jakarta, Indonesia. 61 54
19469619 2009
44
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. 54 61
19123955 2009
45
Oral epithelial hyperplasia in diabetes mellitus. 61 54
20067171 2009
46
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. 61 54
18486529 2008
47
Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. 61 54
18485796 2008
48
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. 61 54
18701437 2008
49
Multiple aberrations of chromosome 3p detected in oral premalignant lesions. 54 61
19138989 2008
50
Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. 61 54
18555592 2008
Sources

Variations for Oral Cancer

About this section

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 888)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149281700 ZFHX3 salivary gland,NS,carcinoma,squamous cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 3
2 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 3
3 COSM87031764 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 3
4 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 3
5 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 3
6 COSM87915681 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 3
7 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 3
8 COSM87968235 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.742C>G p.R248G 17:7674221-7674221 3
9 COSM87910752 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 17:7673579-7673579 3
10 COSM87910495 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 3
11 COSM87898723 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 3
12 COSM87897832 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 3
13 COSM87898431 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 3
14 COSM87904722 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.782+1G>T p.? 17:7674180-7674180 3
15 COSM87907089 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.587G>C p.R196P 17:7674944-7674944 3
16 COSM87897745 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
17 COSM87897883 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 3
18 COSM87901886 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 3
19 COSM88420642 THRA salivary gland,mouth floor,carcinoma,NS c.1162C>T p.R388W 17:40093071-40093071 3
20 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,NS c.324A>C p.K108N 9:99129081-99129081 3
21 COSM96852092 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 3
22 COSM85452528 TCF3 salivary gland,NS,carcinoma,squamous cell carcinoma c.173C>T p.S58F 19:1632378-1632378 3
23 COSM92119498 SUZ12 salivary gland,NS,carcinoma,squamous cell carcinoma c.766C>T p.R256C 17:31975656-31975656 3
24 COSM92119935 SUZ12 salivary gland,NS,carcinoma,squamous cell carcinoma c.1976A>G p.H659R 17:31998759-31998759 3
25 COSM140247567 SUPT5H salivary gland,tongue,carcinoma,NS c.1094G>T p.R365L 19:39468812-39468812 3
26 COSM96394806 STK40 salivary gland,NS,carcinoma,squamous cell carcinoma c.97G>T p.G33* 1:36361236-36361236 3
27 COSM99809024 SPEN salivary gland,NS,carcinoma,squamous cell carcinoma c.1648C>T p.R550C 1:15920882-15920882 3
28 COSM84585112 SOX17 salivary gland,NS,carcinoma,squamous cell carcinoma c.1181C>T p.A394V 8:54459931-54459931 3
29 COSM84673917 SMO salivary gland,NS,carcinoma,squamous cell carcinoma c.1513C>T p.P505S 7:129210409-129210409 3
30 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 3
31 COSM89654419 SMARCA4 salivary gland,NS,carcinoma,squamous cell carcinoma c.3967C>T p.R1323C 19:11034929-11034929 3
32 COSM100403983 SMARCA2 salivary gland,tongue,carcinoma,NS c.2564G>A p.R855Q 9:2086866-2086866 3
33 COSM91388484 SMAD4 salivary gland,NS,carcinoma,squamous cell carcinoma c.1565C>T p.P522L 18:51078373-51078373 3
34 COSM87293136 SLC26A2 salivary gland,mouth floor,carcinoma,NS c.1474C>T p.R492W 5:149981067-149981067 3
35 COSM92478792 SH2B3 salivary gland,NS,carcinoma,squamous cell carcinoma c.241G>A p.D81N 12:111418386-111418386 3
36 COSM92476801 SH2B3 salivary gland,NS,carcinoma,squamous cell carcinoma c.1226G>A p.G409E 12:111447534-111447534 3
37 COSM89628192 SF3B1 salivary gland,minor,carcinoma,NS c.3254C>T p.A1085V 2:197397997-197397997 3
38 COSM103044749 SETD2 salivary gland,minor,carcinoma,NS c.6379C>T p.Q2127* 3:47057405-47057405 3
39 COSM103026313 SETD2 salivary gland,NS,carcinoma,squamous cell carcinoma c.5503C>T p.P1835S 3:47084277-47084277 3
40 COSM87217226 RUNX1 salivary gland,minor,carcinoma,NS c.958C>T p.R320* 21:34799310-34799310 3
41 COSM88240392 RPTOR salivary gland,NS,carcinoma,squamous cell carcinoma c.3788C>T p.P1263L 17:80962556-80962556 3
42 COSM88241411 RPTOR salivary gland,minor,carcinoma,NS c.734C>T p.A245V 17:80754089-80754089 3
43 COSM93209608 RPS6KA4 salivary gland,NS,carcinoma,squamous cell carcinoma c.967C>T p.R323C 11:64365361-64365361 3
44 COSM93843490 ROS1 salivary gland,NS,carcinoma,squamous cell carcinoma c.5794G>A p.E1932K 6:117320014-117320014 3
45 COSM93850828 ROS1 salivary gland,NS,carcinoma,squamous cell carcinoma c.2878G>A p.G960R 6:117365676-117365676 3
46 COSM93850819 ROS1 salivary gland,NS,carcinoma,squamous cell carcinoma c.5211A>T p.E1737D 6:117337209-117337209 3
47 COSM140180846 RNF43 salivary gland,NS,carcinoma,squamous cell carcinoma c.434G>A p.R145Q 17:58363542-58363542 3
48 COSM85226318 RNF38 salivary gland,mouth floor,carcinoma,NS c.623A>G p.H208R 9:36357890-36357890 3
49 COSM97325050 RIT1 salivary gland,mouth floor,carcinoma,NS c.286C>G p.Q96E 1:155904733-155904733 3
50 COSM84136617 RICTOR salivary gland,NS,carcinoma,squamous cell carcinoma c.712C>T p.P238S 5:38981908-38981908 3

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer
Sources

Expression for Oral Cancer

About this section
Search GEO for disease gene expression data for Oral Cancer.
Sources

Pathways for Oral Cancer

About this section

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.8 TP53 MMP9 EGFR CDKN2A CDH1 CCND1
2
Relaxin signaling pathway 36
Show member pathways
 12.58 MMP9 MMP2 KRT19 KRT13 EGFR
3
Glioma 36
Show member pathways
 12.52 TP53 RARB MMP9 MMP2 EGFR CDKN2A
4
Gastric cancer 36
Show member pathways
 12.48 TP53 RARB GSTT1 GSTM3 GSTM1 EGFR
5
MicroRNAs in cancer 36
12.35 TP53 MMP9 MIR345 MIR31 MIR21 EGFR
6
Cell cycle 36 1
12.29 TP53 CDKN2A CDH1 CCND1
7
Proteoglycans in cancer 36
12.27 TP53 MMP9 MMP2 MIR21 EGFR CCND1
8
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.24 TP53 MMP2 EGFR CCND1
9
Colorectal Cancer Metastasis 63
12.13 TP53 MMP9 MMP2 EGFR CDH1 CCND1
10
Pathways in cancer 36
12.09 TP53 RARB MMP9 MMP2 GSTT1 GSTM3
11
Integrated Breast Cancer Pathway 1
12.07 TP53 EGFR CDH1 CCND1
12
Fluid shear stress and atherosclerosis 36
12.02 TP53 MMP9 MMP2 GSTT1 GSTM3 GSTM1
13
Spinal Cord Injury 1
11.94 TP53 MMP9 EGFR CCND1
14
Interleukin-4 and 13 signaling 65
11.89 TP53 MMP9 MMP2 CCND1
15
Glioblastoma Multiforme 63
11.87 TP53 EGFR CDKN2A CCND1
16
Small cell lung cancer 36
11.78 TP53 RARB CCND1
17
Platinum drug resistance 36
11.72 TP53 GSTT1 GSTM3 GSTM1 CDKN2A
18
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 60
Show member pathways
 11.71 GSTT1 GSTM1 CYP1A1
19
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.69 MMP9 MMP2 CDH1 CCND1
20
AGE/RAGE pathway 1
11.62 MMP9 MMP2 EGFR
21
LPA receptor mediated events 1
11.6 MMP9 MMP2 EGFR
22
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.58 MMP9 MMP2 CCND1
23
Cell adhesion_ECM remodeling 22
11.56 MMP9 MMP2 EGFR
24
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.54 MMP9 MMP2 EGFR CCND1
25
Photodynamic therapy-induced AP-1 survival signaling. 1
11.47 TP53 MMP2 EGFR CDKN2A CCND1
26
Bladder cancer 36 1
11.36 TP53 MMP9 MMP2 EGFR CDKN2A CDH1
27
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.27 MMP9 MMP2 CCND1
28
Naphthalene metabolism 22
11.07 GSTT1 GSTM1 CYP1A1
Sources

GO Terms for Oral Cancer

About this section

Biological processes related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 TP53 RARB MMP9 MIR21 EGFR
2 positive regulation of apoptotic process GO:0043065 9.91 TP53 RARB MMP9 MIR21 CDKN2A
3 response to organic substance GO:0010033 9.77 CYP1A1 CDH1 CCND1
4 response to estrogen GO:0043627 9.7 KRT19 GSTM3 CCND1
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MMP9 MMP2 MIR21
6 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.65 EGFR CYP1A1 CCND1
7 embryo implantation GO:0007566 9.63 MMP9 MMP2 MIR21
8 glutathione metabolic process GO:0006749 9.61 GSTT1 GSTM3 GSTM1
9 replicative senescence GO:0090399 9.58 TP53 CDKN2A
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 TP53 EGFR
11 negative regulation of cartilage development GO:0061037 9.56 RARB MIR21
12 xenobiotic catabolic process GO:0042178 9.55 GSTM3 GSTM1
13 mitotic G1 DNA damage checkpoint GO:0031571 9.54 TP53 CCND1
14 cellular response to reactive oxygen species GO:0034614 9.54 MMP9 MMP2 EGFR
15 nitrobenzene metabolic process GO:0018916 9.4 GSTM3 GSTM1
16 glutathione derivative biosynthetic process GO:1901687 9.33 GSTT1 GSTM3 GSTM1
17 cellular detoxification of nitrogen compound GO:0070458 9.32 GSTM3 GSTM1
18 response to UV-A GO:0070141 9.26 EGFR CCND1
19 liver development GO:0001889 9.26 RARB EGFR CYP1A1 CCND1
20 positive regulation of protein phosphorylation GO:0001934 9.02 MMP9 MIR21 EGFR CDK2AP1 CCND1

Molecular functions related to Oral Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutathione binding GO:0043295 9.16 GSTM3 GSTM1
2 glutathione transferase activity GO:0004364 9.13 GSTT1 GSTM3 GSTM1
3 enzyme binding GO:0019899 9.1 TP53 GSTM3 GSTM1 EGFR CYP1A1 CCND1
Sources

Sources for Oral Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....